

CLAIMS

5 What is claimed is:

1. A dosage form comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide.
2. The dosage form of claim 1 wherein said dosage form is a solid.
3. The dosage form of claim 1 wherein said dosage form is a liquid.
- 10 4. The dosage form of claim 1 wherein said dosage form is a liquid suspension.
5. The dosage form of claim 4 wherein the concentration of the alpha-2 adrenergic agonist is from 0.1% to 2%.
6. The method of claim 4 wherein the concentration of the trefoil factor
- 15 family peptide is from 0.1% to 1%.
7. The dosage form of claim 1 wherein said alpha-2-adrenergic agonist is selected from the group consisting of imidazole -2-thiones, quinoxaline derivatives, imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, and mixtures thereof, or is a
- 20 pharmaceutically acceptable salt thereof.
8. The dosage form of claim 1 wherein said alpha-2-adrenergic agonist comprises brimonidine or a pharmaceutically acceptable salt thereof.
9. The dosage form of claim 1 which further comprises a mucoadhesive agent.
- 25 10. The dosage form of claim 1 wherein the trefoil factor family peptide is TFF1.
11. The dosage form of claim 1 wherein the trefoil factor family peptide is TFF2.
12. The dosage form of claim 1 wherein the trefoil factor family peptide is
- 30 TFF3.
13. A method of treating glaucoma or reducing intraocular pressure comprising topically administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to an eye of a mammal suffering from glaucoma.

14. The method of claim 13 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in separate compositions.

15. The method of claim 13 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in a single composition.

5 16. A method of treating a gastrointestinal disorder comprising administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to a mammal suffering from said disorder.

17. The method of claim 16 wherein the gastrointestinal disorder comprises Crohn's disease, ulcerative colitis, gastritis, irritable bowel disease and chronic
10 visceral pain.

18. The method of claim 16 wherein the gastrointestinal disorder comprises ulcerative colitis.

19. The method of claim 16 wherein the gastrointestinal disorder comprises irritable bowel disease.

15